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Because established vaccine technologies are not likely to provide protection against human immu-
nodeficiency virus (HIV) infection, efforts are being focused on defining immunologic and virologic
correlates of HIV containment with the hope that this information will provide direction to new
approaches for HIV vaccination.The development of antiviral vaccines
is historically rooted in efforts that
were not based on an understanding
of the immunopathogenesis of dis-
ease. The first successful antiviral vac-
cine, the vaccine to prevent smallpox,
was administered by Edward Jenner in
1796 without knowledge of the etio-
logic agent of the disease, an under-
standing of how smallpox is transmit-
ted, or what physiologic mechanisms
might prevent the acquisition of infec-
tion (Jenner, 1801). Learning that milk-
maids were protected from developing
smallpox and hypothesizing that expo-
sure to cowpox might confer protec-
tion against smallpox, Jenner exposed
young James Phipps to fluid extracted
from a cowpox lesion and showed that
the boy was subsequently protected
from acquiring smallpox. Thus, a so-
phisticated understanding of how
specific immune effector mechanisms
might mediate clearance of the small-
pox virus was not employed at the
time to develop an effective smallpox
vaccine.
Although recent decades have wit-
nessed an explosion in our under-
standing of the immune mechanisms
that can mediate the containment of
viral replication, vaccines in the mod-
ern era have been developed based
on studies in which only a single im-
mune effector response, an antiviral
IgG titer, is monitored. Effective vac-
cines against diverse viruses such as
poliovirus and hepatitis B virus were
developed by benchmarking a critical
antiviral IgG titer that was associated
with protection and by devising vacci-366 Immunity 27, September 2007 ª2007nation strategies that reproducibly
and safely generated those antibody
responses (Nathanson and Bodian,
1962). This approach to vaccine devel-
opment did not require an understand-
ing of the differences in disease patho-
genesis associated with infections by
different viruses.
Viral infections can be prevented by
a variety of vaccine strategies (Table 1)
(Plotkin and Orenstein, 1999). Building
on Jenner’s experience in the 18th cen-
tury, a number of effective live-virus
vaccines have been developed. A
pathogenic virus is passaged in vitro,
which results in an accumulation of
mutations. The resulting mutated virus
retains the capacity to replicate in vivo
but has an attenuated pathogenic po-
tential. Vaccination with such a non-
pathogenic virus initiates an infection
that induces a robust immune re-
sponse comprised of not only anti-
body and CD4+ T lymphocyte re-
sponses, but also CD8+ T lymphocyte
responses. These CD8+ T lymphocyte
responses are generated because of
the MHC class I processing of viral
proteins that occurs in the setting of
active replication of the vaccine virus
in vivo. The measles and chickenpox
vaccines currently in use were created
by this approach. A major limitation of
this vaccine strategy is the possibility
that a vaccine virus that has the capac-
ity to mutate may revert to a patho-
genic state in inoculated individuals
and could potentially be transmitted
from a vaccinee to immunologically
naive individuals who come into con-
tact with the vaccinee.Elsevier Inc.A number of antiviral vaccine strate-
gies have also been developed that
make use of nonreplicating immuno-
gens, including inactivated viruses,
recombinant proteins, and virus-like
particles (VLPs). Chemical treatment
or irradiation of a virus can eliminate
the ability of that virus to replicate
while leaving it in a conformation that
can present protective epitopes to
cells of the immune system. The cur-
rently used hepatitis A vaccine is
such an immunogen. Viral proteins
expressed in cell lines can also be
administered as immunogens. The
hepatitis B vaccine is based on this
approach. Finally, the recently devel-
oped papillomavirus vaccine is a VLP,
an immunogen created through the
expression of structural viral proteins
that come together in vitro to form
nonreplicating, noninfectious parti-
cles. The inactivated virus-, recombi-
nant protein-, and VLP-based vac-
cines all induce antibody and CD4+ T
lymphocyte responses because these
immunogens undergo MHC class II
processing. However, because they
do not replicate in vivo, these vaccine
antigens do not undergo MHC class I
processing and therefore do not elicit
CD8+ T lymphocyte responses.
Although the application of these es-
tablished approaches for vaccination
has provided many successful immu-
nogens, these strategies have not
been able to elicit immune responses
that confer universal control against
other viruses that cause considerable
morbidity and mortality in human
populations. Although the available
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in Humans
Strategy Immunity Immunogen Example
Nonreplicating
immunogens
CD4+ T cell;
antibody
inactivated virus hepatitis A virus
recombinant protein hepatitis B virus
virus-like particles papillomavirus
Live virus CD8+, CD4+ T cell;
antibody
live attenuated virus measlesvaccines against influenza virus can
provide protection against some circu-
lating viral isolates, they cannot confer
protection against all circulating vi-
ruses. No successful vaccine has been
developed for use against hepatitis C
virus (HCV). Interestingly, influenza vi-
rus and HCV share the property that
they cannot be contained in a human
population by a vaccine that induces
an antibody response to a single con-
served region of a viral protein. Anti-
bodies specific for the influenza princi-
pal neutralizing determinant (PND), the
hemagglutinin protein, can neutralize
the virus, blocking its ability to infect
a target cell. However, the hemaggluti-
nin undergoes rapid and continuous
mutational evolution, which allows it
to escape from a vaccine-elicited neu-
tralizing antibody response. Like influ-
enza, HCV generates mutant progeny
virions at a rapid rate, permitting it to
evade a vaccine-induced neutralizing
antibody response. Moreover, there
is no evidence that HCV even has a
PND. Therefore, viruses of this type
cannot be consistently controlled by
vaccine-induced antibody responses.
The human immunodeficiency virus
(HIV) is the best-studied virus for which
an established technology is unlikely
to yield an effective vaccine. Like
influenza virus and HCV, HIV mutates
at an extraordinarily rapid rate, allow-
ing it to evade a neutralizing antibody
response (Wei et al., 2003). Therefore,
currently available nonreplicating vac-
cine prototypes will not generate an
HIV antibody response that will neu-
tralize a diversity of HIV isolates. In
fact, accruing evidence suggests that
CD8+ T lymphocytes are of central im-
portance in HIV containment (Schmitz
et al., 1999). Although live-virus vac-
cines can induce effective anti-HIV
CD8+ T lymphocyte immunity, studiesin the simian immunodeficiency virus
(SIV) macaque model for the acquired
immunodeficiency syndrome (AIDS)
have shown that prototype live attenu-
ated vaccines can rapidly mutate from
a nonpathogenic to a pathogenic form,
making this approach unsafe for HIV
vaccination (Whatmore et al., 1995).
Additional technologies for inducing
CD8+ T lymphocyte immunity to HIV
are therefore currently being evalu-
ated, including the use of plasmid
DNA and live recombinant vectors.
However, nonhuman primate studies
suggest that such CD8+ T lympho-
cyte-based vaccination approaches
may generate immune responses that
partially contain HIV replication after
the initiation of infection but may not
be able to block infection by the virus
(Letvin et al., 2006). Thus, it is possible
that neither established nor recently
developed vaccine technologies will
be able to confer absolute protection
against infection by HIV.
Frustrated by the difficulties being
encountered in attempts to create an
effective HIV vaccine, the AIDS vac-
cine research community has turned
its attention to defining immunologic
and virologic correlates of HIV contain-
ment. Investigators anticipate that an
effective HIV vaccine strategy might
emerge from a better understanding
of both the biology of HIV transmission
and the immunologic events that are
triggered by early virus replication.
These investigators assume that
a better understanding of HIV immu-
nobiology will uncover specific vulner-
abilities of the virus or previously unex-
plored immune effector mechanisms
that might be harnessed through vac-
cination.
Studies being pursued to define
these correlates of protection include
explorations of the virology, genetics,Immunity 27,and immunology of early HIV replica-
tion. Investigators are searching for
examples of the precise virus that is
transmitted from infected to uninfec-
ted individuals, hoping to demonstrate
idiosyncratic sequences or qualitative
properties that might distinguish the
transmitted virus from viruses isolated
from chronically infected individuals
(Derdeyn et al., 2004). These studies
are being donewith the hope that there
may be properties of the transmitted
virus that can be specifically targeted
through vaccination. There is a well-
documented heterogeneity in the suc-
cess that various individuals have in
controlling early HIV replication, with
some manifesting poor and others
manifesting effective early control of
virus. To elucidate the mechanisms
accounting for this heterogeneity, ge-
netic determinants of early viral control
are being explored through genomic
analyses of defined populations of
acutely infected individuals (Fellay
et al., 2007). These genomic analyses
may uncover novel immune effector
mechanisms that might be harnessed
through vaccination to control early
HIV replication. Most transmission of
HIV occurs across a mucosal surface
during sexual contact, so considerable
effort is being devoted to characteriz-
ing the early events in mucosal trans-
mission of HIV (Morrow et al., 2007).
These studies are focused on clarifying
how HIV traverses a mucosal mem-
brane. Is the virus crossing a mucosal
membrane by transcytosis through
mucosal cells, by movement between
cells, or by trafficking across a tear in
the mucosal membrane? The answers
to questions such as this will determine
how important it might be to generate
mucosal immunity to HIV through vac-
cination. Finally, because of concern
that adaptive immune effector cells
from a vaccine-primed memory popu-
lation of lymphocytes emerge too
slowly to contain the early spread of
HIV after the transmission event,
attention is being focused on deter-
mining whether innate immune mech-
anisms might contribute to HIV control
in the acutely infected individual. In-
vestigators hope that such innate anti-
viral mechanisms might be effectively
harnessed through novel vaccination
strategies.September 2007 ª2007 Elsevier Inc. 367
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against HIV infection that has received
considerable attention in studies of
AIDS immunopathogenesis is the phe-
nomenon of exposed, uninfected indi-
viduals. Cohorts of commercial sex
workers in Africa have been described
that are repeatedly exposed to HIV
through sexual contact but do not
become infected by the virus (Fowke
et al., 1996). This phenomenon, if
real, represents sterile protection or
abortive infections rather than simply
improved control of viral replication af-
ter the initiation of infection. The bio-
logic events underlying this protection
would provide an important target for
vaccine development, so considerable
effort has been focused on determin-
ing whether the protection is a result
of a measurable immunologic effector
function. To date, both local and sys-
temic HIV-specific immune responses
have been described in these individ-
uals. Moreover, this immunity includes
both cellular and humoral responses.
However, the immunity that has been
described in these individuals is
sporadic and the cellular immune
responses are of low frequency.
Correlates of immune protection are
also being sought in studies of ma-
caques that are vaccinated and then
challenged with a pathogenic SIV iso-
late. Although experiments in the SIV
macaque model of HIV infection have
not demonstrated a safe vaccine strat-
egy that confers sterile protection from
infection, impressive viral control has
been documented in monkeys that
have received live, attenuated vac-
cines and in monkeys that have been
infected with one strain of SIV and
are then superinfected with another
strain of the virus (Wyand et al.,
1999). Efforts are therefore being fo-
cused on characterizing the immune
mechanisms that contribute to this
protection.
Some investigators are evaluating
HIV controllers, individuals who are in-
fected with HIV but are able to contain
viral replication for periods of many
years without antiretroviral drug ther-
apy (Deeks and Walker, 2007, in this
issue of Immunity). These studies are
focusing on host genetics, immune re-
sponses, and the properties of the in-
fecting virus. The hope is that a vaccine368 Immunity 27, September 2007 ª2007might be developed that mobilizes
the same mechanisms that mediate
protection against HIV replication in
these rare individuals and, in so doing,
facilitate control of HIV replication in
people who become infected.
The most ambitious studies cur-
rently being pursued to define corre-
lates of immune protection against
HIV are a series of human clinical HIV
vaccine trials that are being sponsored
by the National Institutes of Health.
These include trials of a recombinant
adenovirus vaccine developed by
Merck Research Laboratories and
a plasmid DNA prime with recombi-
nant adenovirus boost developed by
the Vaccine Research Center (VRC),
National Institutes of Health (Dubey
et al., 2007; Catanzaro et al., 2006;
Graham et al., 2006). The Merck vac-
cine is being evaluated in two separate
trials of 3000 volunteers, and the VRC
vaccine is being evaluated in a trial
of 8000 volunteers. Because these
vaccine approaches have been specif-
ically developed to elicit cellular immu-
nity, considerable attention has been
focused on devising durable and re-
producible assays to evaluate vaccine-
elicited cellular immune responses.
Theassaysdeveloped for theseclinical
trials include highly quantitative elispot
and intracellular cytokine staining (ICS)
assays. Peripheral blood lymphocytes
of vaccinees are exposed to pools of
peptides spanning the HIV proteins
employed in the vaccines, and cyto-
kine production by the lymphocytes is
measured by these technologies.
These vaccine trials employ not only
unique assays but also unique clinical
endpoints. Impressive SIV control has
been observed in vaccinated monkeys
as a consequence of the early emer-
gence of a potent virus-specific cyto-
toxic T lymphocyte response after viral
infection (Letvin et al., 2006). Associ-
ated with that virologic control is a
striking protection against the loss of
activated memory CD4+ T lympho-
cytes. Based on these findings in non-
humanprimatestudies, thehumanvac-
cine trials include as endpoints not only
acquisition of virus but also the control
of virus and memory CD4+ T lympho-
cyte loss after infection. It is hoped
that associationswill become apparent
between the quantity and quality ofElsevier Inc.vaccine-elicited cellular immune re-
sponses and the degree of clinical
protection conferred by those immune
responses in the human vaccinees.
Correlates of immune protection are
also being defined to guide the devel-
opment of an effective vaccine against
HCV. Like for HIV infections, experi-
mental work suggests that CD8+ lym-
phocytes may be critical for containing
the replication of HCV. This has been
demonstrated in nonhuman primate
studies both by showing poor control
of virus in animals depleted of CD8+
lymphocytes and by showing protec-
tion against virus challenge in animals
after vaccination with a live recombi-
nant vector expressing only nonstruc-
tural proteins of HCV. Experimental
systems are being developed to clarify
the role of neutralizing antibody re-
sponses in the containment of HCV.
The selection of vaccine strategies to
evaluate for protection against HCV
will be made based on the findings in
these studies to define correlates of
immune protection against this virus.
It is important to recognize that vac-
cines can sometimes provide protec-
tion against infection by mechanisms
that differ from those that are operative
in the setting of natural infection. For
example, it has recently been shown
in rhesus monkeys that in vivo B cell
depletion has no effect on measles vi-
rus clearance, whereas CD8+ lympho-
cyte depletion substantially impedes
clearance of the virus (Permar et al.,
2004). These observations suggest
that cellular immunity rather than hu-
moral immunity is of central impor-
tance in the containment of measles
spread. Nevertheless, human vaccine
trials have shown that an inactivated
virus vaccine, an immunogen that can
elicit antibodies but not CD8+ CTL
populations, can confer protection
against acquisition of measles (Guinee
et al., 1966). Thus, viral clearance in
the setting of natural infection is medi-
ated by cellular immunity, whereas
vaccine-induced antibodies can con-
fer protective immunity. These obser-
vations demonstrate that there may
not be only a single correlate of protec-
tion against a particular viral infection.
Further, vaccine-induced immune
responses can confer protection by
mechanisms that are not associated
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systemic antibody response elicited
by the inactivated-virus polio vaccine
does not block polio virus transmis-
sion. Rather, it diminishes poliovirus
replication systemically after mucosal
transmission has occurred, blocking
viral seeding of the central nervous
system (Bodian, 1955). This highly ef-
fective vaccine, therefore, aborts the
natural course of a mucosally acquired
poliovirus infection without acting at
the site of transmission.
Underlying any consideration of
strategies for developing a vaccine for
HIV is the question of what should we
expect an HIV vaccine to do? Specifi-
cally, can a vaccine be developed
that actually confers sterile protection
against the virus? Many highly effec-
tive antiviral vaccines that are in use
worldwide protect against the devel-
opment of disease but do not protect
against infection by the virus. In stud-
ies done in monkey AIDS models, SIV
infection cannot be blocked by live
attenuated virus vaccines or prior in-
fection with a modestly divergent SIV
strain (Wyand et al., 1999). Although
sterile protection against a simian hu-
man immunodeficiency virus (SHIV)
challenge has been described in mon-
keys infused with neutralizing mono-
clonal antibodies, these antibodies
must be present at extraordinarily
high titers in the experimental animals.
These studies all raise the possibility
that sterile protection against HIV
may not be achievable (Mascola
et al., 1999). The efforts to define cor-relates of protection against HIV repli-
cation will provide an important test
of the concept that an intense study
of the immunopathogenesis of a viral
infection will inform the development
of an effective vaccine against that
virus.
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